Loading…
← CockpitCompetitor Analysis › 6589.TW EirGenix, Inc.Open in the cockpit ↗

EirGenix, Inc.6589.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum leader 86
Mkt cap
$444M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$1.33M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.7 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
119 days
17 Mar 2027
Close · TWDNT$51.50
1D-2.8%
1W-0.4%
1M+0.8%
3M0.0%
6M+15.5%
YTD-16.5%
1Y-22.3%
ATR %4.5%
52w lowhigh38.9% off high

What EirGenix does

No business profile yet.

EirGenix at a glance

Size EirGenix (6589.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $444M, the 466th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$51.50 on 18 Nov 2026.

Performance Over six months the shares gained 15.5%, against -10.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 57.8% over the last twelve months (peer median -2.2%); the operating margin is -50.7% (peer median -4.5%).

Valuation It trades at 9.9× enterprise value to sales against a peer median of 5.2× (7th most expensive of 15).

Capital Return on invested capital runs 12.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20266589.TW 116Peer median 90
Six months, rebased to 100: EirGenix against the median of its 20 peers (local-currency closes).

EirGenix financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$1.48BNT$1.01BNT$1.01BNT$1.02BNT$1.48B
Revenue growth—0%-1%-31%—
Gross profitNT$643MNT$64.4MNT$56.1MNT$118MNT$661M
EBITDAn/a-NT$560M-NT$652M-NT$793M-NT$126M
Net income-NT$502M-NT$761M-NT$698M-NT$915M-NT$116M
Free cash flown/a-NT$903M-NT$1.23B-NT$1.56B-NT$491M
Capital expendituren/aNT$1.62BNT$928MNT$775MNT$820M
Total debtn/aNT$1.71BNT$901MNT$465MNT$459M

Quarterly statements and history in the cockpit →

EirGenix competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-40%-20%0%+20%ARVNIRLA0007106037391151801789041960STTKPRTA25096712DMAC6547KMDAFENC476830CADL6589.TW6-month return →1-month return →
Up and to the right = strong over both horizons. EirGenix is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×100×200×000710603739115180041960PRTA250967126547FENC4768306589.TWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. EirGenix is the large dot.

EirGenix competitors and peer comparison

How EirGenix compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

EirGenix against its 20 peers (data as of 18 Nov 2026)
Measure6589.TWPeer medianRank in peer set
1-month return+0.8%-12.7%4th highest of 21
6-month return+15.5%-10.7%4th highest of 19
Distance from 52-week high-38.9%-39.7%10th highest of 21
Revenue growth (TTM)+57.8%-2.2%4th highest of 16
Operating margin-50.7%-4.5%6th lowest of 16
EV / Sales9.9×5.2×7th most expensive of 15
ROIC minus cost of capital-12.7 pp-6.0 pp5th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a

Questions

Which companies are EirGenix's closest peers?
The cockpit's peer set: Arvinas (ARVN), IRulya Therapeutics (IRLA), Berry Genomics (000710.SZ), Qingdao Vland Biotech (603739.SS), Qurient (115180.KS), Scinopharm Taiwan (1789.TW), Komipharm International (041960.KS), Shattuck Labs (STTK).
Is EirGenix expensive compared with its peers?
On ev / sales it trades at 9.9× against a peer median of 5.2×, 7th most expensive of 15 in its peer set.
How has EirGenix stock performed?
Over six months to 18 Nov 2026 the shares returned +15.5% against -10.7% for the median peer; over one year -22.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.